Current Approach to the Management of Neutropenia

Journal of Intensive Care Medicine

Volumn 10, Issue 6, 1995, Pages 283-293

  Liles, W Conrad ^a   Dale, David C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 3; PENICILLIN DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC THERAPY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; FEVER; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRANULOCYTE TRANSFUSION; HEMATOPOIESIS; HOST RESISTANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKEMIA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0028884468     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/088506669501000603     Document Type: Article

References (112)

1. Craddock C. Defenses of the body: the initiators of defense, the ready reserves, and the scavengers. In: Wintrobe Mm, ed. Blood, pure and eloquent. New York: McGraw-Hill, 1980: 417–454
2. Lehrer R Ganz T Selsted M. Neutrophils and host defense. Ann Intern Med 1988; 109: 127–142
3. Schimpff S. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986; 80 (suppl 5C): 13–20
4. Bodey G Buckley M Sathe Y Freireich E. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 1966; 64: 328–340
5. Hughes W Armstrong D Bodey G. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381–396
6. Pizzo P. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323–1332
7. Dale D Guerry D Wewerka J. Chronic neutropenia. Medicine 1979; 58: 128–144
8. Pizzo P Robichaud K Wesley R Commers J. Fever in the pediatric and young adult patient with cancer: a prospective study of 1001 episodes. Medicine 1982; 61: 153–165
9. Mullen C Buchanan G. Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. J Clin Oncol 1990; 8: 1998–2004
10. Pizzo P. After empiric therapy: what to do until the granulocyte comes back. Rev Infect Dis 1987; 9: 214–219
11. Brown E Talbot G Provencher M Cassileth P. Anaerobic bacteremia in patients with acute leukemia. Infect Control Hosp Epidemiol 1989; 10: 65–69
12. Golde D. Production, distribution and fate of neutrophils. In: Williams Wj, Beutler Md, Erslev Aj, Lichtman Ma, eds. Hematology, ed 4. New York: McGraw-Hill, 1990: 795–801
13. Dancey J Deubelbeiss K Harker L Finch C. Neutrophil kinetics in man. J Clin Invest 1976; 58: 705–715
14. Dale D. Neutropenia. In: Williams Wj, ed. Hematology, ed 5. New York: McGraw-Hill, 1995
15. Carlos T Harlan J. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068–2101
16. Macgregor R. Alcohol and immune defense. JAMA 1986; 256: 1474–1479
17. Wickramasinghe S Fida S. Bone marrow cells from vitamin B12- and folate-deficient patients misincorporate uracil into DNA. Blood 1994; 83: 1656–1661
18. Price T Lee M Dale D Finch C. Neutrophil kinetics in chronic neutropenia. Blood 1979; 54: 581–594
19. Glenn J Cotton D Wesley R Pizzo P. Anorectal infections in patients with malignancies. Rev Infect Dis 1988; 10: 42–52
20. McFarland L Mulligan M Kwok R Stamm W. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204–210
21. Flynn P Van Hooser B Gigliotti F. Atypical mycobacterial infections of Hickman catheter exit sites. Pediatr Infect Dis J 1988; 7: 510–513
22. Pizzo P Robichaud K Gill F Witebsky F. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101–111
23. Meunier-Carpentier F Kiehn T Armstrong D. Fungemia in the immunocompromised host. Am J Med 1981; 71: 363–370
24. Bodey G. Fungal infections complicating acute leukemia. J Chronic Dis 1966; 19: 667–687
25. Walsh T Pizzo A. Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis 1988; 7: 460–475
26. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14 (suppl 1): 43-53
27. Rinaldi M. Emerging opportunists. Infect Dis Clin North Am 1989; 7: 460–475
28. Anaissie E Kantarjian H Ro J. The emerging role of fusarium infections in patients with cancer. Medicine 1988; 67: 77–83
29. Wingard J Merz W Rinaldi M. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274–1277
30. Haron E Feld R Tuffnell P. Hepatic candidiasis: an increasing problem in immunocompromised patients. Am J Med 1987; 83: 17–26
31. Thaler M Pastakia B Shawker T. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108: 88–100
32. Weinberger M Elattar I Marshall D. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine 1992; 71: 24–43
33. Press O Ramsey P Larson E. Hickman catheter infections in patients with malignancies. Medicine 1984; 63: 189–200
34. Allen V Smith C Probes C. The value of skin biopsies in febrile, neutropenic, immunocompromised children. Am J Dis Child 1986; 140: 459–461
35. Fainstein V Bodey G McCredie K. Coagulation abnormalities induced by b-lactam antibiotics in cancer patients. J Infect Dis 1983; 148: 745–750
36. Conly J Chubb H Bow E Louie T. Hypothrombinemia in febrile neutropenic patients with cancer: association with antimicrobial suppression of intestinal microflora. J Infect Dis 1984; 150: 202–212
37. Pizzo P. Granulocytopenia and cancer therapy: past problems, current solutions, future challenges. Cancer 1984; 54(suppl):2649–2661
38. Armstrong D. Empiric therapy for the immunocompromised host. Rev Infect Dis 1991; 13 (suppl 9): 763-769
39. Hathorn J Rubin M Pizzo P. Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy. Antimicrob Agents Chemother 1987; 31: 971–977
40. Bodey G. Empirical antibiotic therapy for fever in neutropenic patients. Clin Infect Dis 1993; 17 (suppl 2): 378-384
41. Rubenstein E Rolston K Benjamin R. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71: 3640–3646
42. Talcott J Siegel R Finberg R Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316–322
43. Talcott J Whalen A Clark J. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia; a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994; 12: 107–114
44. Malik I Khan W Aziz A Karim M. Self-administered antibiotic therapy for chemotherapy-induced low-risk febrile neutropenia in patients with non-hematologic neoplasms. Clin Infect Dis 1994; 19: 522–527
45. Malik I Khan W Karim M. Feasibility of out-patient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995 (in press)
46. Dugdale D Ramsey P. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990; 89: 137–141
47. Benerza D Kiehn T Gold J. Prospective study of infection in indwelling central venous catheters using quantitative blood cultures. Am J Med 1988; 85: 495–498
48. Klasterskey J Vamecq G Cappel R. Effects of the combination of gentamicin and carbenicillin on the bactericidal activity of serum. J Infect Dis 1972; 125: 183–186
49. Bodey G Jadeja L Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985; 145: 1621–1629
50. Dejongh C Joshi J Thompson B. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 1986; 80: 101–111
51. Winston D Winston G Bruckner D. Controlled trials of beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am J Med 1988; 85 (suppl 1A): 21–30
52. Mortimer J Miller S Black D. Comparison of cefoperazpne and mezlocillin with imipenem as empiric therapy in febrile granulocytopenic patients. Am J Med 1988; 85 (suppl 1A): 17–20
53. Anaissie E Fainstein V Bodey G. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. Am J Med 1988; 84: 581–589
54. Rotstein C Cimino M Winkey K. Cefoperazone plus piperacillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients. Am J Med 1988; 85 (suppl 1A): 36–39
55. Gutmann L Williamson R Kitzic M Acar J. Synergism and antagonism in double beta-lactam antibiotic combinations. Am J Med 1986; 80 (suppl 50: 21–29
56. Pizzo P Hathorn J Hiemenz J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–558
57. Verhagen C De Pauw B De Witte T. Randomized prospective study of ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1987; 31: 191–196
58. Wade J Johnson D Bustamante C. Monotherapy for empiric treatment of fever in granulocytopenic cancer patients. Am J Med 1986; 80 (suppl 5C): 89–95
59. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692–1698
60. Rubin M Hathorn J Marshall D. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988; 108: 30–35
61. Granowetten L Wells H Lange B. Ceftazidime with or without vancomycin vs. cephalothin, carbenicillin and gentamicin as initial therapy of the febrile neutropenic pediatric cancer patient: Pediatr Infect Dis J 1988; 7: 165–170
62. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime plus amikacin with or without vancomycin as empirical therapy of fever in cancer patients with granulocytopenia (abstract 18). Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, 1988
63. Ramphal R Bolger M Obion D. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992; 36: 1062–1067
64. Shenep J Hughes W Roberson P. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl. J Med 1988; 319: 1053–1058
65. Karp J Hick J Angelopulos C. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Am J Med 1986; 81: 237–242
66. Kramer B Ramphal R Rand K. Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother 1986; 30: 64–68
67. Murray B. Antibiotic resistance among enterococci: current problems and management strategies. Curr Clin Topic Infect Dis 1991; 11: 94–117
68. Moellering R. Emergence of enterococcus as a significant pathogen. Clin Infect Dis 1992; 14: 1173–1178
69. Leclercq R Dutka-Malen S Brisson-Noel A. Resistance of enterococci to aminoglycosides and glycopeptides. Clin Infect Dis 1992; 15: 495–501
70. Shales D Binczewski B Rice L. Emerging antimicrobial resistance and the immunocompromised host. Clin Infect Dis 1993; 17 (suppl 2): S527–S536
71. Pizzo P Ladisch S Robichaud K. Treatment of gram-positive septicemia in cancer patients. Cancer 1980; 45: 206–207
72. Dinubile M. Stopping antibiotic therapy in neutropenic patients. Ann Intern Med 1988; 108: 289–292
73. Joshi J Schimpff S Tenney J. Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients. Am J Med 1979; 76: 450-457
74. Pizzo P Robichaud K Gill F. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979; 67: 194–200
75. Sugar A. Empiric treatment of fungal infections in the neutropenic host—review of the literature and guidelines for use. Arch Intern Med 1990; 150: 2258–2264
76. Talbot G Provencher M Cassilrth P. Persistent fever after recovery from granulocytopenia in acute leukemia. Arch Intern Med 1988; 148: 129–135
77. Hughes W Kuhn S Chaudhary S. Successful chemprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977; 297: 1419–1426
78. Walsh T Lee J. Prevention of invasive fungal infections in patients with neoplastic diseases. Clin Infect Dis 1993; 17 (suppl 2): S468–S480
79. Menichetti F Del Favero A Martino P. Preventing fungal infection in patients with acute leukemia. fluconazole compared with oral amphotericin B. Ann Intern Med 1994; 120: 913–918
80. Goodman J Winston D Greenfield R. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851
81. Meunier F. Prevention of mycoses in immunocompromised patients. Clin Infect Dis 1987; 9: 408–416
82. Rousey S Russler S Gottlieb M Ash R. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991; 91: 484-492
83. Perfect J Klotman M Gilbert C. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165: 891–897
84. Metcalf D. The colony stimulating factors: discovery, development, and clinical applications. Cancer 1990; 65: 2185–2195
85. Lieschke G Burgess A. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, parts I and II. N Engl J Med 1992; 327: 28–35; 99–106
86. Petersdorf S Dale D. The biology and clinical applications of erythropoietin and the colony-stimulating factors. Adv Intern Med 1994; 40: 366–399
87. Cebon J Layton J Maher D Morstyn G. Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol 1994; 86: 265–274
88. Cebon J Layton J. Measurement and clinical significance of circulating hematopoietic growth factor levels. Curr Opin Hematol 1994; 1: 228–234
89. Lieschke G Grail D Hodgson G. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84: 1737–1746
90. Ozer H (for Am Soc Clin Oncol ad hoc CSF Guidelines Expert Panel). American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994; 12: 2471–2508
91. Crawford J Ozer J Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–170
92. Trillet-Lenoir V Green J Manegold C. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319–324
93. Gisselbrecht C Prentice H Bacigalupo A. Placebo-controlled phase III trial of Ienograstim in bone-marrow transplantation. Lancet 1994; 343: 696–700
94. Gaabrilove J Jakubowski A Scher H. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414–1422
95. Traynor B. Quality of life with filgrastim (r-mentHuG-CSF). In: Morstyn G, Dexter Tm, eds. Filgrastim in clinical practice. New York: Marcel Dekker, 1994; 319–337
96. Dale D Dale D Bonilla M. A randomized controlled phase III trial of recombinant human G-CSF for treatment of severe chronic neutropenia. Blood 1993; 81: 2496–2502
97. Maher D Lieschke G Green M. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Inter Med 1994; 121: 492–501
98. Gasson J. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 1131–1145
99. Nemunaitis J Rabinowe S Singer J. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773–1778
100. Gerhartz H Engelhard M Meusers M. Randomized, double-blind, placebo-controlled, phase III study- of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993; 82: 2329–2339
101. Devries E Biesma B Willemse P. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991; 51: 116–122
102. Bunn P Crowley J Hazuka M. The role of GM-CSF in limited stage SCLC: a randomized phase III study of the Southwest Oncology Group (SWOG) (abstract). Proc A Soc Clin Oncol 1992; 11: 292
103. Marina N Shema S Bowman L. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. Med Pediatr Oncol 1994; 23: 328–334
104. Ganser A. Hematopoietic growth factors in the treatment of the myelodysplastic syndromes. Curr Opin Hematol 1995; 2: 204–209
105. Greenberg P Taylor K Larson R. Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS). Blood 1993; 82: 196a
106. Hoelzer D Seipelt G. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of myeloid leukemia. Curr Opin Hematol 1995; 2: 196–203
107. Menitove J Abrams R. Granulocyte transfusions in neutropenic patients. CRC Crit Rev Oncol Hematol 1987; 7: 89–113
108. Quie P. The white cells: use of granulocyte transfusions. Rev Infect Dis 1987; 9: 189–193
109. Strauss R. Therapeutic granulocyte transfusions in 1993. Blood 1993; 81: 1675–1678
110. Bensinger W Price T Dale D. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81: 1883–1888
111. Liles W Waltersdorph A Klebanoff S. Regulation of apoptosis in Human neutrophils: effects of proinflammatory mediators, protein kinase inhibitors, and antibodies directed against b2-integrins (abstract). Clin Res 1994; 42: 148A
112. Liles W Rodger E Dale D. In vivo administration of granulocyte colony-stimulating factor (G-CSF) to normal human subjects: priming of the respiratory burst and inhibition of apoptosis in neutrophils (abstract). Blood 1994; 84 (suppl l):24a